Tiziana Life Sciences

TLSA

Market cap $192M

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain inflammation and improve cognitive function linked to Long COVID, according to a study published on bioRxiv. The study evaluated foralumab, a fully human anti-CD3 monoclonal antibody administered through the nose, in a mouse model designed to mimic neurological symptoms of Long COVID without direct viral infection of the brain.

Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company's lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company's lead candidate, intranasal foralumab, for Long COVID associated “brain fog”.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the World Parkinson Congress in Phoenix, Arizona in May 2026. The poster, titled “A Phase 2a Study of Intranasal Foralumab in Multiple System Atrophy,” will outline the design and rationale of the ongoing TILS-025 trial, the company said.

BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress, taking place May 24-27, 2026, in Phoenix, Arizona.

The recent data highlight nasal anti-CD3's potential in reversing cognitive decline associated with aging, which is a significant concern in neurodegenerative diseases.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel approach to addressing neuroinflammation associated with aging. The company highlighted that neuro inflammation is widely recognized as a contributing factor to cognitive decline in age-related neurological conditions.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with neuroprotective changes in patients with a progressive form of multiple sclerosis. The late-breaking findings were presented by investigators from Brigham and Women's Hospital in a poster detailing results in 10 patients with non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse activity (PIRA).

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new biomarker data from a late-breaking poster titled “Nasal foralumab downregulates CSF inflammation and upregulates CSF neuroprotective proteomic pathways which correlate with [F-18]PBR06-PET imaging in na-SPMS with PIRA,” which was presented by investigators from Brigham and Women's Hospital, Boston, MA.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that a peer-reviewed study of its experimental intranasal therapy for secondary progressive multiple sclerosis (SPMS) has been published in the journal Neurology Neuroimmunology & Neuroinflammation. The study, titled “Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis,” evaluated intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in 10 patients with non-active SPMS (na-SPMS) who continued to progress despite prior B-cell therapies.

BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology.